Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin

• Autor(a) principal: Maciel, Gustavo Arantes Rosa [UNIFESP]
• Data de Publicação: 2004
• Outros Autores: Soares Junior, José [UNIFESP], Motta, Eduardo Leme Alves da [UNIFESP], Haidar, Mauro Abi [UNIFESP], Lima, Geraldo Rodrigues de [UNIFESP], Baracat, Edmund Chada [UNIFESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1016/j.fertnstert.2003.08.012; http://repositorio.unifesp.br/handle/11600/27591
• topic: polycystic ovary syndrome; metformin; insulin resistance

Objective: To determine the clinical, hormonal, and biochemical effects of metformin therapy in obese and nonobese patients with polycystic ovary syndrome (PCOS).Design: Controlled clinical study.Setting: Department of Gynecology of Federal University of São Paulo, São Paulo, Brazil.Patient(s): Twenty-nine patients with PCOS.Intervention(s): Patients were treated with 500 mg of p.o. metformin t.i.d. for 6 months.Main Outcome Measure(s): Clinical data as well as serum concentrations of sex steroids, sex hormone-binding globulin (SHBG), gonadotropins, leptin, GH, lipids, insulin, and glucose levels were assessed before and after treatment.Result(s): in the metformin group of nonobese patients, the mean fasting serum insulin concentration decreased from a pretreatment value of 12.1 +/- 2.4 to 6.3 +/- 0.6 muU/mL after treatment, and the area under the curve of insulin decreased from 5,189.1 +/- 517.4 to 3,035.6 +/- 208.9 muU/mL per minute. Also in the metformin group of nonobese patients, the mean basal serum total testosterone, free testosterone, and androstenedione concentrations decreased by 38%, 58%, and 30%, respectively. in the obese patients treated with metformin, only free testosterone showed a statistically significant decrease (1.7 +/- 0.2).Conclusion(s): Our data suggest that nonobese patients respond better than obese patients to a 1.5 g/day metformin regimen. (C)2004 by American Society for Reproductive Medicine.